Redipor Success Drives Cherwell Cleanroom Expansion
Cherwell Laboratories, leading supplier of microbiology media and instruments for pharmaceutical and related industries, is continuing with the investment and expansion programme of its cleanroom production facilities. To increase capacity for future demand from Cherwell’s ever growing customer base, Phase II of the expansion programme will boost Redipor microbiological prepared media plate filling and bottle production capabilities. The new cleanroom facility will be further extended by 230 m2 to more than 950 m2.
Once Phase II is completed in early 2014, Cherwell’s facilities will have doubled in size since July 2012. Phase I delivered new inspection and packing facilities to maintain stringent quality requirements in media preparation prior to Phase II’s increase in Redipor production facilities. Uniquely, to ensure utmost quality Cherwell do not package Redipor products straight from the filling line but first hold them to condition, additionally all products then undergo 100% inspection before final packing.
Demand for Cherwell’s Redipor products continues to rise as new customers experience the benefits of a flexible and reliable supply of these exceptionally high-quality prepared media products. Cherwell’s ability to deliver high volume efficiency with small volume flexibility has helped to increase its market share and develop more export markets, such as Poland. Careful selection of new partners in mainland Europe, has also contributed to securing new customers keen to benefit from a full adaptable service for their industrial microbiological prepared media.
Andy Whittard, Managing Director, Cherwell Laboratories, provided further insight into the reasons for Cherwell’s expanding market. “Despite growing interest in rapid methods, the traditional methods for environmental monitoring are still the most widely used and will continue to be for many years to come. This, coupled with some customers’ movement back to UK and European-based manufacturing, is seeing demand for prepared media continue to increase.”
As Cherwell’s production volumes increase from the current 6.5 million agar plates annually, the company will continue to add to its workforce to maintain its efficiency in supply. Cherwell has already recruited five new staff members since the completion of Phase I, with three additional new starters anticipated before the end of 2013.
“Phase II of our cleanroom extension will provide additional manufacturing space to allow us to invest in further production equipment, such as large scale plate filling systems, media preparators and autoclaves,” added Andy Whittard. “By carefully planning and controlling the works around our own production schedules and with our contractor, Envair Projects, we aim to minimise any impact to customers and product lead times.”
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance